STERIS - STE Stock Forecast, Price & News

STERIS plc provides infection prevention and other procedural products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The Dental segment provides hand and powered dental instruments, infection control products, personal protective equipment, and water quality products for dental suite. The company serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is based in Dublin, Ireland.

STERIS Trading Down 0.4 %

Shares of NYSE:STE traded down $0.84 during midday trading on Wednesday, hitting $211.63. 267,039 shares of the company traded hands, compared to its average volume of 488,112. STERIS has a 12-month low of $192.40 and a 12-month high of $255.93. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.35 and a current ratio of 2.03. The stock has a 50-day moving average price of $210.31 and a 200 day moving average price of $224.55. The firm has a market cap of $21.17 billion, a P/E ratio of 56.74 and a beta of 0.71.

STERIS Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, September 23rd. Stockholders of record on Wednesday, September 7th will be issued a dividend of $0.47 per share. This is a boost from STERIS's previous quarterly dividend of $0.43. The ex-dividend date of this dividend is Tuesday, September 6th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.89%. STERIS's dividend payout ratio is presently 46.11%.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. KeyCorp decreased their price objective on shares of STERIS from $256.00 to $240.00 and set an "overweight" rating on the stock in a research report on Thursday, August 4th. JMP Securities reduced their price target on shares of STERIS from $270.00 to $250.00 in a research report on Thursday, August 4th. TheStreet upgraded shares of STERIS from a "c+" rating to a "b" rating in a research report on Tuesday, August 2nd. StockNews.com raised STERIS from a "hold" rating to a "buy" rating in a research note on Thursday, August 11th. Finally, Piper Sandler initiated coverage on STERIS in a research note on Thursday, July 14th. They set an "overweight" rating and a $240.00 price objective for the company. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $252.00.

Insider Activity

In related news, VP John Adam Zangerle sold 2,659 shares of the stock in a transaction that occurred on Wednesday, June 15th. The shares were sold at an average price of $205.31, for a total transaction of $545,919.29. Following the transaction, the vice president now owns 27,936 shares in the company, valued at $5,735,540.16. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.95% of the company's stock.